https://scholars.lib.ntu.edu.tw/handle/123456789/580157
標題: | Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus | 作者: | ANN-LII CHENG Li J. Vaid A.K. Ma B.B.Y. Teh C. Ahn J.B. Bello M. Charoentum C. Chen L.-T. De Lima Lopes G. Jr. Ho G.F. Kong H.L. Lam K.O. Liu T.S. Park Y.S. Sriuranpong V. Sudoyo A.W. Wang J.-Y. Zhang J. Zhang S.Z. Ciardiello F. Köhne C.-H. Shaw M. Kim T.W. |
關鍵字: | Asia; Chemotherapy; Epidermal growth factor receptor (EGFR)-specific monoclonal antibody; KRAS; Targeted therapy | 公開日期: | 2014 | 出版社: | Elsevier Inc. | 卷: | 13 | 期: | 3 | 起(迄)頁: | 145-155 | 來源出版物: | Clinical Colorectal Cancer | 摘要: | Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional 'real-world' experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available. ? 2014 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84908126534&doi=10.1016%2fj.clcc.2014.06.004&partnerID=40&md5=cf7aa0230f10b459dc4f68522be29159 https://scholars.lib.ntu.edu.tw/handle/123456789/580157 |
ISSN: | 1533-0028 | DOI: | 10.1016/j.clcc.2014.06.004 | SDG/關鍵字: | antineoplastic agent; bevacizumab; capecitabine; cetuximab; fluorouracil; folinic acid; gimeracil; irinotecan; oteracil; oxaliplatin; panitumumab; tegafur; UFT; antineoplastic agent; bevacizumab; camptothecin; cetuximab; deoxycytidine; drug combination; epidermal growth factor receptor; fluorouracil; folinic acid; KRAS protein, human; monoclonal antibody; oncoprotein; oteracil; panitumumab; platinum complex; Ras protein; S 1 (combination); tegafur; advanced cancer; Article; Asian; biological therapy; cancer adjuvant therapy; cancer combination chemotherapy; cancer localization; cancer patient; cancer radiotherapy; cancer recurrence; cancer staging; cancer surgery; colon cancer; consensus development; drug efficacy; human; inoperable cancer; inoperable synchronous metastasis; inoperable synchronous metastasis; liver metastasis; lung metastasis; maintenance therapy; metachronous metastasis; metachronous metastasis; metastasis; metastatic colorectal cancer; multimodality cancer therapy; oncogene K ras; patient selection; peritoneum metastasis; phase 3 clinical trial (topic); practice guideline; rectum cancer; wild type; analogs and derivatives; antagonists and inhibitors; Asia; Colonic Neoplasms; computer assisted tomography; consensus development; drug combination; genetics; Liver Neoplasms; Lung Neoplasms; metastasis resection; nuclear magnetic resonance imaging; pathology; Rectal Neoplasms; secondary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fluorouracil; Guideline Adherence; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Metastasectomy; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Practice Guidelines as Topic; Proto-Oncogene Proteins; ras Proteins; Receptor, Epidermal Growth Factor; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。